Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.57 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 6/20 | 0.48 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CDK7 | P50613 | 2/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CCNH | P51946 | 1/20 | 0.45 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559341 | 0.89 | GSK3B (0.47) | GSK3BDYRK1AFLT3MKNK2MKNK1 | |
| SCHEMBL13638487 | 0.87 | GSK3B (0.52) | GSK3BDYRK1AFLT3MKNK2MKNK1 | |
| SCHEMBL3476994 | 0.86 | MAPK8 (0.50) | GSK3BDYRK1AFLT3MKNK2MAPK8 | |
| SCHEMBL4495552 | 0.86 | MAPK8 (0.53) | GSK3BDYRK1AFLT3MKNK2MKNK1 | |
| SCHEMBL3477878 | 0.86 | GSK3B (0.54) | GSK3BDYRK1AFLT3MKNK2MKNK1 | |
| SCHEMBL4491100 | 0.84 | MAPK8 (0.68) | GSK3BDYRK1AFLT3MKNK2MKNK1 | |
| SCHEMBL3477373 | 0.84 | CCNK (0.51) | GSK3BFLT3MKNK2MAPK8MAPK9 | |
| SCHEMBL3473302 | 0.84 | DYRK1A (0.56) | GSK3BDYRK1AFLT3MKNK2MAPK8 | |
| SCHEMBL27636250 | 0.82 | MAPK8 (0.46) | GSK3BDYRK1AFLT3MKNK2MKNK1 | |
| SCHEMBL4503153 | 0.81 | CDK2 (0.47) | GSK3BDYRK1AFLT3MKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | claimed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | claimed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | claimed |
| EP-1615898-B1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2010134939-A2 | MAMMALIAN GENES INVOLVED IN INFECTION | Zirus, Inc. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-7615562-B2 | Such as 2-methyl-4-{5-[2-(2,2,6,6-tetramethyl-piperidin-4-ylamino)-pyrimidin-4-yl]-thiophen-2-yl}-butan-2-ol; tumor necrosis factor inhibitors; immunosuppressants; antiinflammatory agents | NOVARTIS AG (CH) | 2009-11-10 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1615898-A1 | 2-AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | Novartis AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089913-A1 | AMINOPYRIMIDINE DERIVATIVES AND THEIR MEDICAL USE | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043048-A1 | 2-Aminopyrimidine derivatives and their medical use | TPMT, IKBKB, CHUK | GSK3B 906/4885DYRK1A 1869/4885FLT3 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.